Bio-Techne Corp (TECH) News
Filter TECH News Items
TECH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TECH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TECH News From Around the Web
Below are the latest news stories about BIO-TECHNE CORP that investors may wish to consider to help them evaluate TECH as an investment opportunity.
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative MedicineBio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic devel |
ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's TherapeuticsScaleReady, in collaboration with Wilson Wolf Manufacturing and Bio-Techne Corporation, today announced that Seattle Children's Therapeutics, a division of the Seattle Children's Research Institute has been awarded a $125,000 G-Rex Grant. The G-Rex Grant will integrate state-of-the-art advancements into Seattle Children's Therapeutics' G-Rex based CAR-T cell platform. |
BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas. |
BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTECBio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded NKG2C/CD159c antibodies. This follows a similar case from 2023, where Miltenyi was found to have reversed engineered and commercialized Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies. |
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes. |
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEBio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. |
BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENTBio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and development processes. The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex™ System) and liquid chromatography mass spectrometry (BioAccord™ LC-MS System from Waters) to deliver i |
ScaleReady awards a G-Rex® Grant to Moonlight BioScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant. Moonlight Bio's G-Rex® Grant will expedite process development and IND-enabling studies of their lead CAR T cell therapy for the treatment of solid tumors. |
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay. |
BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEYBio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with MedSanTek. Under the agreement, MedSanTek becomes the distributor of Bio-Techne's R&D Systems, Novus, Tocris, Protein Simple, Advanced Cell Diagnostics (ACD), and Asuragen brands across Turkey. |